Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer

Journal of Clinical Oncology

Volumn 25, Issue 1, 2007, Pages 77-84

  Heymann, Jonas J ^a   Benson, Mitchell C ^a   O'Toole, Kathleen M ^a   Malyszko, Bozena ^a   Brody, Rachel ^a   Vecchio, Darleen ^a   Schiff, Peter B ^a   Mansukhani, Mahesh M ^a   Ennis, Ronald D ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANEMIA; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DIGITAL RECTAL EXAMINATION; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLOW UP; GYNECOMASTIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORGASM DISORDER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; RADIATION INJURY; RADIATION RESPONSE; SECOND CANCER; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY URGENCY; WEIGHT GAIN; ADENOCARCINOMA; ADJUVANT THERAPY; METABOLISM; METHODOLOGY; PROSTATE TUMOR; RADIOTHERAPY; RISK; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FLUTAMIDE; HUMANS; LEUPROLIDE; MALE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 35548930787     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.0419     Document Type: Article

References (17)

1. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
2. Hanks GE, Pajak TF, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-3978, 2003
3. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
4. Pilepich MV, Winter K, John MJ, et al: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
5. Denis LJ, Carnelro de Moura JL, Bono A, et al: Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42:119-130, 1993
6. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
7. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Outcomes of external-beam radiation therapy for prostate cancer: A study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 14:2258-2265, 1996
8. Crook J, Ludgate C, Malone S, et al: Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60:15-23, 2004
9. Zietman AL, Nakfoor BM, Prince EA, et al: The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 3:31-36, 1997
10. Zietman AL, Prince EA, Nakfoor BM, et al: Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38:1067-1070, 1997
11. Kaminski JM, Hanlon AL, Joon DL, et al: Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 57:24-28, 2003
12. Dearnaley D, Hall E, Jackson C, et al: Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer. Int J Radiat Oncol Biol Phys 54:134-135, 2002 (suppl)
13. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: Results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105, 2002
14. Consensus statement: Guidelines for PSA following radiation therapy - American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
15. Zietman AL, Dallow KC, McManus PA, et al: Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 47:236-239, 1996
16. Teshima T, Hanks GE, Hanlon AL, et al: Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 39:77-83, 1997
17. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995